Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene reports business update and Q3 2021 financial position
information fournie par Boursorama CP 04/11/2021 à 17:45

- Data presented at ESMO in September provided clinical proof of concept for the intravenous administration of Transgene’s patented oncolytic virus (Invir.IO™ platform)—significantly expanding the market opportunity

- First data from two ongoing Phase I trials of the individualized cancer vaccine TG4050 (myvac® platform) will be communicated in the second half of November 2021

- €40.9 million in cash and cash equivalents as of September 30, 2021, further strengthened by the €17.4 million received in October 2021 from the partial sale of Tasly BioPharmaceuticals shares

- Financial visibility until the end of 2023

.../...

Valeurs associées

TRANSGENE
0,7700 EUR Euronext Paris +1,05%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
89,17 -6,14%
Or
4 235,86 +0,49%
CAC 40
8 200,8 +0,48%
TOTALENERGIES
78 +0,98%
EUR/USD SPOT
1,15825 +0,04%
Chargement...

Pages les plus populaires

L'offre BoursoBank